Heranba Industries concluded its 34th Annual General Meeting on September 28, 2026, with shareholders approving all six agenda items, including the adoption of audited financial statements for FY26. The meeting was conducted via video conferencing, with detailed voting results disclosed on September 30, 2026.

The board reported that the statutory auditors' report and the secretarial audit report contained no qualifications or adverse remarks. This clean audit opinion signals compliance with regulatory standards for the period under review.

Key resolutions passed

Shareholders voted on several ordinary and special business items. The re-appointment of senior leadership was a primary focus, alongside the ratification of auditor remuneration. All resolutions were passed with requisite majority.

Voting results and participation

The voting process was overseen by scrutinizer CS Nirmal Gupta of M/s. GMJ & Associates. Remote e-voting facilities were available from September 24 to September 27, 2026. During the meeting, an additional 15-minute voting window was provided for members who had not cast their votes earlier.

The total number of shareholders as on the cut-off date of September 21, 2026, stood at 66,652. Of these, 75 shareholders participated in the meeting through Video Conferencing, comprising 11 from the Promoter Group and 64 from the public. No shareholders attended in person or through proxy.

What the numbers show

The voting data reveals a significant concentration of voting power among promoters, who hold 29,987,138 shares out of a total outstanding base of 40,013,467. Promoters voted 100% of their shares in favour of all six resolutions. In contrast, public participation remained low; non-institutional public shareholders voted only 4.04% of their holdings, while institutional public shareholders voted 6.76% of theirs. Despite this low turnout, the sheer volume of promoter votes ensured that every resolution passed with over 99.99% support among votes polled.

Leadership continuity

The meeting saw the presence of the entire board, including independent directors and committee heads. Mr. Sadashiv Kanyana Shetty chaired the session, while Mr. Raghuram Kanyana Shetty served as Managing Director. Other directors present included Mr. Raunak Raghuram Shetty, Mr. Shiraj Sadashiv Shetty, and Mr. Roshan Raghuram Shetty, all serving as Whole Time Directors.

Independent directors attending included Mr. Mulky Vishwanatha Shetty, Mr. Anilkumar Mohanraj Marlecha, Mr. Ganesh Narayan Vanmali, Ms. Reshma Dagdu Wadkar, and Mr. Omprakash Singh. The statutory auditors, represented by Mr. N Jayendran of M/s. N V C & Associates LLP, were also present.

Heranba Industries reported standalone revenue from operations of ₹1,755.55 crore for FY26, a 17.4% increase from ₹1,495.90 crore in FY25, driven by strong volume growth in domestic technicals.

The company's 34th Annual General Meeting is scheduled for Monday, September 28, 2026 at 4:00 PM (IST) through Video Conferencing/Other Audio-Visual Means. The record date for remote e-voting eligibility is September 21, 2026, and the remote e-voting window runs from September 24, 2026 at 9:00 AM to September 27, 2026 at 5:00 PM.

FY26 Financial Performance

Despite healthy revenue growth, profitability remained under pressure from soft price realisations and a shift in product mix. EBITDA margin moderated to 7.3% from 8.4% in FY25, while higher finance costs weighed further on the bottom line.

On a consolidated basis, the group recorded revenue from operations of ₹1,594.99 crore in FY26 against ₹1,409.73 crore in FY25, a growth of 13.1%. The consolidated group reported a Loss After Tax of ₹77.56 crore compared to a Profit After Tax of ₹2.25 crore in FY25, primarily impacted by losses in subsidiary operations, particularly Heranba Organics Private Limited.

Business Vertical Performance

Domestic technicals led growth with sales of ₹781 crore in FY26, accounting for 44% of total sales, up from ₹542 crore (36% share) in FY25. Export technicals remained subdued at ₹304 crore under continued global pricing pressure, while export formulations rose to ₹196 crore from ₹117 crore, aided by new registrations coming into effect.

Key Financial Ratios

The debt-equity ratio rose to 0.49 from 0.26, reflecting fresh borrowings taken during the year. The net capital turnover ratio improved to 10.55 from 6.75, driven by higher sales and a decrease in working capital.

AGM Agenda and Corporate Actions

The 34th AGM will transact the following business:

• Adoption of audited standalone and consolidated financial statements for the year ended March 31, 2026
• Re-appointment of Sadashiv K. Shetty (DIN: 00038681) as director retiring by rotation
• Re-appointment of Raghuram K. Shetty (DIN: 00038703) as director retiring by rotation
• Ratification of remuneration of ₹2,00,000 plus GST payable to M/s. Tapan Gaitonde & Co., Cost Accountants, for FY2026-27
• Re-appointment of Ms. Reshma D. Wadkar (DIN: 09394615) as Non-Executive Independent Woman Director for a second term of five consecutive years from November 11, 2026 to November 10, 2031
• Re-appointment of Mr. Shiraj S. Shetty (DIN: 06609014) as Whole Time Director designated as Executive Director for five years from November 11, 2026 to November 10, 2031

The Board has not recommended any dividend for FY2025-26. The Register of Members and Share Transfer Books will remain closed from September 22, 2026 to September 28, 2026 (both days inclusive).

R&D and CSR Highlights

Heranba spent ₹7.20 crore on R&D in FY26, representing 0.41% of standalone turnover. The R&D team commercialised 2 herbicide actives, 2 fungicide actives, 1 insecticide active, and 2 advanced intermediates at operational scale during the year, and developed over 20 new formulations.

CSR expenditure for FY26 stood at ₹2.15 crore against a statutory obligation of ₹2.10 crore, covering education infrastructure, health and social awareness, and women empowerment initiatives.

Manufacturing and Operational Highlights

The company operates 7 manufacturing and packaging facilities with aggregate Technicals and Intermediates capacity of 26,700 MTPA and Formulations capacity of 30,000 MTPA, supported by 421 reactors across all facilities. The company holds 1,128 cumulative product registrations across 55 countries, with 269 registrations in pipeline, and exports to 85+ countries.